Abstract
To evaluate the effect and adverse reactions of Seratia Marcescens Anticancer Vaccine ( S311) in the treatment of malignant pleural effusions. 0. 32 mg of S311 was administered into intracavity once a week, for successive three weeks, after draining off the pleural cavity completely by thoracocentesis or chest drainage. Two hundred and forty-one patients with malignant effusions finished the arrangement of S311 therapy. The overall response rate was 92. 1%. The main adverse reactions were fever and pleuritic pain. Some patients had chill, dyspnea, nausea and vomiting. Liver dysfunction was observed in a few cases. S311 is an effective drug for malignant pleural effusions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
